Q-omics provides the consensus-scored GNRHR profile across patient tissues and cancer cell-line models. GNRHR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GNRHR is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, GNRHR RNA expression shows 19,077 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where GNRHR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNRHR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNRHR survival associations across molecular data types. GNRHR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNRHR RNA expression–survival associations across cancer types. High GNRHR expression shows unfavorable associations in UVM, THCA and ACC, but favorable associations in UCS, ESCA and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for GNRHR RNA expression.
This table summarizes GNRHR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GNRHR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNRHR shows lower tumor expression in THCA, COAD and ESCA and higher tumor expression in LUSC, KICH and LUAD. The THCA box plot shows higher GNRHR RNA expression in normal versus tumor tissue (log2 FC = −0.141, t-test p < 0.001).
This table shows molecular features associated with GNRHR in patient tissues and cancer cell lines. In patient samples, GNRHR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNRHR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
